Anne Li March 11th, 2018
A molecule on glioblastoma cells that could be used as a target for genetically engineered immune cells has been identified. Researchers at the University of North Carolina found a molecule called CSPG4 in two thirds of tumour samples from 46 patients with glioblastoma. Dr Martin Pule, a Cancer Research UK-funded immunotherapy expert, said finding CSPG4 on the majority of glioblastoma cells suggests it could be tested as a possible treatment target for a broad range of patients.
See original article at: http://www.cancerresearchuk.org/about-us/cancer-news/news-report/2018-03-01-aggressive-brain-tumours-carry-potential-target-for-engineered-immune-cells#